THE USE OF ANTINEOPLASTIC DRUGS AND RALATED REIMBURSEMENT POLICY IN CHINA

• At: AbuDhabi (United Arab Emirates) (2019)
• Type: Poster
• Poster code: POS-HMIS-022
• By: KUAI, Liping (Science and Technology Development Center of CPA, China)
• Co-author(s): Yinyu zhou: administration office, Science&Technology development center of CPA, beijing, China
  Liping Kuai: policy research department, Science&technology development center of CPA, beijing, China
  Ran zhang: policy research department, Science@Technology Development Center of CPA, beijing, China
  Dongyan Xu: policy research department, Science & Technology Development Center of CPA, beijing, China
  Jingran liu: policy research department, Science and Technology Development Center of CPA, Beijing, China
  
• Abstract:

  Background

   With the increase of cancer’s incidence, China's antineoplastic drugs’ market had developed rapidly.

  The Chinese government was highly concerned about antineoplastic drugs use and strive to increase the affordability of the antineoplastic drugs.

  Methods

  The use of antineoplastic drugs in the membership hospitals of CMEI were analyzed
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login